A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study

References

• Anon. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• EU ROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results [EUROASPIRE Study Group]. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569–82
   Google Scholar
• Anon. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995–1001
   Google Scholar
• Mark L, Zamolyi K, Pados G, et al. Achieving the target lipid levels in Hungary, 2004. Orv Hetil 2005;146:147–52
   PubMedGoogle Scholar
• Athyros VG, Elisaf M, Mikhailidis DP. Undertreatment of dyslipidaemia in Greece. Atherosclerosis 2004;177:215–6
   PubMed Web of Science ®Google Scholar
• Di Martino M, Degli Esposti L, Ruffo P, et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol 2005;61:225–30
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz FJ, Marin Ibanez A, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain [The REALITY Study]. Pharmacoeconomics 2004;22(Suppl 3):1–12
   Google Scholar
• Ose L, Skjeldestad FE, Bakken IJ, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 2006;6:121–8
   PubMedGoogle Scholar
• Marcelino J, Feingold K. Inadequate treatment with HMGCoA reductase inhibitors by health care providers. Am J Med 1996;100:605–10
   PubMed Web of Science ®Google Scholar
• Monkman D. Treating dyslipidaemia in primary care. The gap between policy and reality is large in the UK. Br Med J 2000;321:1299–300
   Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice [Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice]. Eur Heart J 2003;24:1601–10
   Google Scholar
• McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 2005;96:60E–66E
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425–35
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003;326:1423
   Google Scholar
• LIPITOR* (atorvastatin calcium) Prescribing Information. Pfizer Inc., March 2007. Available at: www.pfizer.com/hml/pi’s/lipitorpi.pdf [accessed 29 May 2007]
   Google Scholar
• Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   PubMed Web of Science ®Google Scholar
• Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the Alliance study. J Am Coll Cardiol 2004;44:1772–9
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96
   PubMed Web of Science ®Google Scholar
• Athyros V, Papageorgiou A, Mercouris B, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220–8
   PubMed Web of Science ®Google Scholar
• Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 2005;149:e1
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Saponaro J, et al. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol 2005;46:594–9
   PubMed Web of Science ®Google Scholar
• Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2006;191:135–46
   PubMed Web of Science ®Google Scholar
• Lock K, Pomerleau J, Causer L, et al. The global burden of disease attributable to low consumption of fruit and vegetables: implications for the global strategy on diet. Bull World Health Organ 2005;83:100–8
   PubMed Web of Science ®Google Scholar
• Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. J Am Med Assoc 2004;292:1433–9
   PubMed Web of Science ®Google Scholar
• Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676–83
   PubMed Web of Science ®Google Scholar
• Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study – Observational (CALIPSO). Can J Cardiol 2005;21:1187–93
   PubMed Web of Science ®Google Scholar
• NCEP. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III]. J Am Med Assoc 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc 2000;284:3043–5
   PubMed Web of Science ®Google Scholar
• Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   PubMed Web of Science ®Google Scholar
• Brown A, Bakker-Arkema R, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665–72
   PubMed Web of Science ®Google Scholar
• Andrews T, Ballantyne C, Hsia J, Kramer J. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185–91
   PubMed Web of Science ®Google Scholar
• Aguilar-Salinas C, Gomez-Perez F, Posadas-Romero C, et al. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Atherosclerosis 2000;152: 489–96
   Google Scholar
• McPherson R, Angus C, Murray P, Genest J. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: the Women’s Atorvastatin Trial on Cholesterol (WATCH). Am Heart J 2001;141:949–56
   PubMed Web of Science ®Google Scholar
• Nissen S, Tuzcu E, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2004;291:1071–80
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. J Am Med Assoc 2005;294:2437–45
   PubMed Web of Science ®Google Scholar
• Jones P, Davidson M, Stein E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152–60
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464–73
   PubMed Web of Science ®Google Scholar
• Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H–9H
   Google Scholar
• Onat A, Sari I, Yazici M, et al. Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol 2006;108:89–95
   PubMed Web of Science ®Google Scholar
• Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14 236 patients. Am J Cardiol 2006;97:61–7
   PubMed Web of Science ®Google Scholar
• Cannon C, Braunwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004;350:1495–504
   PubMed Web of Science ®Google Scholar
• Kinlay S, Schwartz G, Olsson A, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560–6
   PubMed Web of Science ®Google Scholar
• Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 2003;92:670–6
   PubMed Web of Science ®Google Scholar